Psoriasis - Pipeline Review, Q1 2011

Description: Psoriasis - Pipeline Review, Q1 2011

Summary

Global Markets Direct's, 'Psoriasis - Pipeline Review, Q1 2011', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Psoriasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Psoriasis Overview
Therapeutics Development
Psoriasis Therapeutics under Development by Companies
Psoriasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Companies Involved in Psoriasis Therapeutics Development
Universities/Institutes Involved in Psoriasis Therapeutics Development
Psoriasis - Therapeutics Assessment
Late Stage Drug Profiles – Companies
Late Stage Drug Profiles – Universities/Institutes
Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Psoriasis, 2011
Products under Development for Psoriasis – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Daichi Sankyo Company, Ltd, 2011
Merck & Co., Inc., 2011
Micromet, Inc., 2011
Novo Nordisk A/S, 2011
Albany Molecular Research, Inc., 2011
Nycemed International Management GmbH, 2011
Novartis AG, 2011
Actelion Ltd, 2011
Biocon Limited, 2011
Cephalon, Inc., 2011
Eisai Co., Ltd., 2011
GTC Biotherapeutics, Inc., 2011
LEO Pharma A/S, 2011
Mitsubishi Tanabe Pharma Corporation, 2011
Pfizer Inc., 2011
Rigel Pharmaceuticals, Inc., 2011
Santarus, Inc., 2011
Gemkab A/S, 2011
Merck KGaA, 2011
Addex Pharmaceuticals, 2011
InNexus Biotechnology Inc., 2011
Can-Fite BioPharma Ltd., 2011
Idera Pharmaceuticals, Inc., 2011
Manhattan Pharmaceuticals, Inc., 2011
Almirall, S.A., 2011
Lupin Limited, 2011
NicOx SA, 2011
Compugen Ltd., 2011
CytoGenix, Inc., 2011
Bio3 Research S.r.l, 2011
Tolerx, Inc., 2011
ProMetic Life Sciences Inc., 2011
Genizon BioSciences, Inc., 2011
Hanall Pharmaceutical Co., Ltd., 2011
Cytos Biotechnology AG, 2011
AnGes MG, Inc., 2011
Biotie Therapies Corp., 2011
Sosei Group Corporation, 2011
Provectus Pharmaceuticals, Inc., 2011
Synta Pharmaceuticals Corp., 2011
Hybrigenics S.A., 2011
Piramal Life Sciences Limited, 2011
Paloma Pharmaceuticals, Inc., 2011
Digna Biotech, S.L., 2011
Angelini Group, 2011
D-Pharm Ltd., 2011
Affimed Therapeutics AG, 2011
Viron Therapeutics, Inc., 2011
Jenrin Discovery, Inc., 2011
Probiodrug AG, 2011
Physica Pharma, 2011
BioMAS Ltd., 2011
Neovacs SA, 2011
MIKA Pharma GmbH, 2011
Cosmix Molecular Biologicals GmbH, 2011
CREABILIS Therapeutics S.r.l., 2011
IMTM GmbH, 2011
Anacor Pharmaceuticals, Inc., 2011
JADO Technologies GmbH, 2011
Circassia Holdings Ltd., 2011
Allozyne, Inc., 2011
Gene Signal International SA., 2011
Syntrix Biosystems, Inc., 2011
MediQuest Therapeutics, Inc., 2011
Xention Limited, 2011
TcL Pharma SAS, 2011
Inimex Pharmaceuticals, Inc., 2011
Y's Therapeutics Co., Ltd., 2011
Welichem Biotech Inc., 2011
ELORAC, Inc., 2011
CBio Limited, 2011
Allostera Pharma Inc., 2011
SWITCH Biotech LLC, 2011
Hy BioPharma Inc., 2011
BioCis Pharma Ltd., 2011
Laboratorios SALVAT S.A., 2011
KAHR medical Ltd., 2011
Synphora AB, 2011
Aphoenix, Inc., 2011
Kemin Industries, Inc., 2011
Immune Control, Inc., 2011
Cellceutix Pharmaceuticals, Inc., 2011
Femta Pharmaceuticals, Inc., 2011
Sinapis Pharma, Inc, 2011
Mycenax Biotech Inc., 2011
DOLTHERA GmbH, 2011
Immune Technologies and Medicine, 2011
Mantecorp Industria Quimica e Farmaceutica Ltda, 2011
Advancell, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Psoriasis, 2011
Products under Development for Psoriasis – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/1574048/](http://www.researchandmarkets.com/reports/1574048/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psoriasis - Pipeline Review, Q1 2011
Web Address: http://www.researchandmarkets.com/reports/1574048/
Office Code: SCD2IL2S

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Electronic - Site License:</td>
<td>USD 1000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World